Brian Barr, MD
Cardiovascular Disease · Baltimore, MDNPI 1306007398
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $62,325 of the $62,445 with a category attached, or 99.8%. Astellas Pharma Global Development accounts for 99.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $61,800 and has fallen 99.8% since, to $120 in 2024. Among cardiovascular disease clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 4 payments — averaging $15,611 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma Global Development$62K
- Change Healthcare Technologies, LLC$525
- Medtronic$120
What the payments were for
- Consulting fees$62,325100%
- Food & beverage$1200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma Global Development | 1 | $61,800 |
| Change Healthcare Technologies, LLC | 2 | $525 |
| Medtronic | 1 | $120 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYRBETRIQ$61,800
- Change Healthcare Cardiology$525
- ONYX FRONTIER$120
How this compares
$62,445 in reported general payments places this provider in the 95th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 191 | $221,573 |
| EntrestoSacubitril/Valsartan | 87 | $105,633 |
| XareltoRivaroxaban | 77 | $94,289 |
| JardianceEmpagliflozin | 28 | $24,935 |
| Atorvastatin Calcium | 315 | $4,862 |
| Metoprolol Succinate | 237 | $4,734 |
| Rosuvastatin Calcium | 104 | $2,903 |
| Amlodipine Besylate | 198 | $1,908 |
| Losartan Potassium | 162 | $1,843 |
| Chlorthalidone | 69 | $1,792 |
| Nifedipine ErNifedipine | 50 | $1,497 |
| Ezetimibe | 31 | $1,298 |
| Lisinopril | 92 | $975 |
| Spironolactone | 82 | $874 |
| Candesartan Cilexetil | 15 | $792 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Baltimore
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
- Charles CummingsBaltimore$114K
- John RickardBaltimore$109K
- Christopher DefilippiBaltimore$101K
- David KassBaltimore$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.